These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 21069942)

  • 21. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
    Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
    Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anti-angiogenesis: a new concept in therapy of solid malignancies?].
    Schweigerer L
    Med Klin (Munich); 1995 Dec; 90(12):709-12. PubMed ID: 8583988
    [No Abstract]   [Full Text] [Related]  

  • 23. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H
    Biochem Pharmacol; 2010 Sep; 80(5):550-60. PubMed ID: 20371362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and preclinical trials of isolated liver perfusion for advanced liver tumors: primary liver tumors.
    Lowy AM; Curley SA
    Surg Oncol Clin N Am; 1996 Apr; 5(2):429-41. PubMed ID: 9019362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Zhu AX
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
    [No Abstract]   [Full Text] [Related]  

  • 26. From the guest editors: introduction to local therapies in the treatment of liver cancer.
    Ensminger WD; Chang AE
    Cancer J; 2010; 16(2):91-2. PubMed ID: 20404604
    [No Abstract]   [Full Text] [Related]  

  • 27. Closing in on cancer.
    Park A
    Time; 2001 May; 157(20):60, 62. PubMed ID: 11383110
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeting the unmet medical need: the Abbott Laboratories oncology approach.
    Carlson DM; Steinberg JL; Gordon G
    Clin Adv Hematol Oncol; 2005 Sep; 3(9):703-10. PubMed ID: 16224444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer 'cure' article stirs up hot debate.
    Wadman M
    Nature; 1998 May; 393(6681):104-5. PubMed ID: 9603508
    [No Abstract]   [Full Text] [Related]  

  • 30. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 31. Taking down tumors: vascular disrupting agents entering clinical trials.
    O'Hanlon LH
    J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
    [No Abstract]   [Full Text] [Related]  

  • 32. [Molecular structure and abnormal expression of angiopoietin-2 and antiangiogenic targeting therapy of hepatocelluar carcinoma].
    GU WJ; YAO DF
    Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):398-400. PubMed ID: 19497214
    [No Abstract]   [Full Text] [Related]  

  • 33. Vascular endothelium summary statement III: Cancer prevention and control.
    Reed E; Seffrin J; Giavazzi R; van Hinsbergh V; Madeddu P
    Vascul Pharmacol; 2007 May; 46(5):321-3. PubMed ID: 17234459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. At a crossroads in oncology.
    Kamb A
    Curr Opin Pharmacol; 2010 Aug; 10(4):356-61. PubMed ID: 20542731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiangiogenic therapy at a crossroads: clinical trial results and future directions.
    Ellis LM
    J Clin Oncol; 2003 Dec; 21(23 Suppl):281s-283s. PubMed ID: 14645411
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapeutics: a glimpse of the future.
    Goldring O
    Nature; 1998 Mar; 392(6674):420. PubMed ID: 9537332
    [No Abstract]   [Full Text] [Related]  

  • 37. [Targeted anticancer drugs and their development].
    Kervinen J; Gahmberg CG
    Duodecim; 2004; 120(19):2323-30. PubMed ID: 15565985
    [No Abstract]   [Full Text] [Related]  

  • 38. Show me your signaling--and I'll tell you who you are.
    Schattenberg JM; Galle PR
    J Hepatol; 2009 Oct; 51(4):638-9. PubMed ID: 19592126
    [No Abstract]   [Full Text] [Related]  

  • 39. Emergence of aspirin as a promising chemopreventive and chemotherapeutic agent for liver cancer.
    Xia H; Hui KM
    Cell Death Dis; 2017 Oct; 8(10):e3112. PubMed ID: 29022914
    [No Abstract]   [Full Text] [Related]  

  • 40. The real challenge of the translational process: management of expectations.
    Katz AJ
    Muscle Nerve; 2011 Feb; 43(2):155-6. PubMed ID: 21254076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.